Tecentriq meets PFS endpoint in first-line TNBC

Genentech Inc. said Tecentriq atezolizumab met the co-primary endpoint of improving progression-free survival in the Phase III IMpassion130 trial as first-line treatment of triple-negative breast cancer. The Roche (SIX:ROG; OTCQX:RHHBY) unit said the data are the first positive Phase III readout for an immunotherapy in the indication.

IMpassion130 enrolled 902 patients with locally advanced or metastatic TNBC who have not received prior systemic therapy for metastatic breast cancer and compared Tecentriq plus Abraxane nab-paclitaxel vs. placebo plus Abraxane. Genentech said Tecentriq plus Abraxane significantly improved PFS in both the intent-to-treat (ITT) and PD-L1-positive populations vs. placebo plus Abraxane...